<DOC>
	<DOCNO>NCT00004644</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate whether high-dose acyclovir decrease acute long-term morbidity mortality neonates central nervous system disseminate herpes simplex virus ( HSV ) infection . II . Evaluate whether high-dose acyclovir safe tolerate newborn . III . Assess resistance antiviral medication . IV . Amplify disease classification purpose predict prognosis . V. Assess change viral excretion pattern . VI . Evaluate whether antigens antibody specific HSV glycoprotein within cerebrospinal fluid ( CSF ) predict long-term neurologic outcome . VII . Evaluate whether specific antigen antibody CSF appear late treatment indicative insidious reactivation virus brain .</brief_summary>
	<brief_title>Phase I/II Study High-Dose Acyclovir Central Nervous System Disseminated Neonatal Herpes Simplex Virus Infection</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Neonates treat intravenous acyclovir 21 day . Patients follow day 28 , 6 , 12 , 24 , 36 , 48 month .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Herpes simplex virus infection disseminate localized central nervous system Virologically confirm 1 follow method : Tissue culture Monoclonal antibody stain Electron microscopy Prior/Concurrent Therapy No concurrent antiviral therapy Patient Characteristics Life expectancy : No imminent demise Birth weight least 1200 g Gestational age 32 week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Days</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>herpes simplex virus infection</keyword>
	<keyword>herpesvirus infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>viral infection</keyword>
</DOC>